U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Search AHRQ

For an exact phrase match, enclose search terms in double quotes.

Go to Advanced Search
Go to Basic Search

Results

Total Results: 2,207 records

Showing results for "drug".

  1. Version-3-Immunity-After-Covid-19-Appendix-Table-B-1 (xls file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/version-3-immunity-after-COVID-19-appendix-table-B-1.xlsx
    January 24, 2022 - KQ1_IgG Duration_n=3 Observational studies examining IgG Duration Author Year Title PMID Link/URL Country Study Design Length of follow-up (Months) Population category Population Description Data Source Study Period Inclusion criteria Exclusion criteria Total N Age: Mean (SD) years or Median (IQR) Race stratifi…

  2. Layout 1 (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cystic-fibrosis-hgh_executive.pdf
    October 01, 2010 - Food and Drug Administration include the treatment of growth hormone deficiency, idiopathic short stature

  3. Weight-Gain-Prevention Executive (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/weight-gain-prevention_executive.pdf
    January 01, 2020 - Expert Opin Drug Saf. 2009;8(5):573-84. PMID: 19538102. 16. Sestak I, Harvie M, Howell A, et al.

  4. Renal Artery Stenosis Management Strategies: An Updated Comparative Effectiveness Review (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/renal-update_executive.pdf
    August 01, 2016 - Food and Drug Administration, World Health Organization, and ClinicalTrials.gov databases.

  5. Methods Future Research Needs Number 8: Framework for Considering Study Designs (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/study-design-framework_research.pdf
    March 01, 2012 - samples in RCTs may be too small or not sufficiently generalizable as part of the evaluation of a drug

  6. Cannabis-2023-Surv-Rep-4-Tables-E-1-E-4 (xls file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-tables-E-1-E-4.xlsx
    January 01, 2023 - study enrollment Median 64 13 NR NR NR NR NR NR NR Patients with major psychiatric disorder or past drug … preparation Mean 50 23 NR NR NR NR NR Mean 48 Patients with bipolar disorder or psychosis excluded Comparison drug

  7. Cannabis-2023-Surv-Rep-1-App-F (xls file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-1-app-F.xlsx
    January 01, 2023 - study enrollment Median 64 13 NR NR NR NR NR NR NR Patients with major psychiatric disorder or past drug … preparation Mean 50 23 NR NR NR NR NR Mean 48 Patients with bipolar disorder or psychosis excluded Comparison drug

  8. Cannabis-2022-Surv-Rep-4-Tables-F1-4 (xls file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-tables-F1-4.xlsx
    January 01, 2022 - study enrollment Median 64 13 NR NR NR NR NR NR NR Patients with major psychiatric disorder or past drug … preparation Mean 50 23 NR NR NR NR NR Mean 48 Patients with bipolar disorder or psychosis excluded Comparison drug

  9. Lung-Cancer-Nonsurgical-Therapies Executive (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/lung-cancer-nonsurgical-therapies_executive.pdf
    June 01, 2013 - Food and Drug Administration Web site, ClinicalTrials.gov, and conference abstracts (American Society

  10. CERs Report cover (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/hip-feature-treatment-future_research.pdf
    September 23, 2010 - As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed

  11. Febrile-Infants-Diagnosis-Management Executive (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/febrile-infants-diagnosis-management_executive.pdf
    March 01, 2012 - In one study, 0.4 percent of the included infants developed drug-related rash and 18.9 percent had

  12. Trauma-Interventions-Maltreatment-Child Executive (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/trauma-interventions-maltreatment-child_executive.pdf
    April 01, 2013 - Childhood victimization and illicit drug use in middle adulthood.

  13. Topic Brief: Interventions to Decrease Hospital Length of Stay (pdf file)

    effectivehealthcare-admin.ahrq.gov/system/files/docs/topic-brief-hospital-length-of-stay.pdf
    November 01, 2019 - Does the nomination represent a health care drug, intervention, device, technology, or health care

  14. Executive Summary CER 171: Noninvasive Testing for Coronary Artery Disease (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/coronary-artery-disease-testing_executive.pdf
    March 01, 2011 - Executive Summary CER 171: Noninvasive Testing for Coronary Artery Disease 1 Comparative Effectiveness Review Number 171 Noninvasive Testing for Coronary Artery Disease Executive Summary Background Nature and Burden of Coronary Artery Disease The public health and economic burdens of coronary artery dise…

  15. Future Research Needs for the Comparative Effectiveness of Breathing Exercises and/or Retraining Techniques in the Treatment of Asthma (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/asthma-treatment-future_research.pdf
    September 01, 2012 - Food and Drug Administration Medical and Statistical Reviews), clinical trial registries (e.g., National

  16. Disposition of Comments Report for Core Needle and Open Surgical Biopsy for Diagnosis of Breast Lesions: An Update to the 2009 Report (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/breast-biopsy-update_disposition-comments.pdf
    September 10, 2014 - Disposition of Comments Report for Core Needle and Open Surgical Biopsy for Diagnosis of Breast Lesions: An Update to the 2009 Report Comparative Effectiveness Review Disposition of Comments Report Research Review Title: Core Needle and Open Surgical Biopsy for Diagnosis of Breast Lesions: An Update to th…

  17. Disposition of Comments for Technical Brief 23 Genetic Testing (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/genetic-testing-developmental-disabilities_disposition-comments.pdf
    June 30, 2015 - Food and Drug Administration (FDA) or Clinical Laboratory Improvement Amendments (CLIA) pathway.

  18. Towards a Framework for Communicating Confidence in Methodological Recommendations for Systematic Reviews and Meta-Analyses (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methodological-recommendations-framework-communications_research.pdf
    September 01, 2013 - antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug

  19. Disposition of Comments_Comparative Effectiveness Review No. 269_Respectful Maternity Care: Dissemination and Implementation of Perinatal Safety Culture To Improve Equitable Maternal Healthcare Delivery and Outcomes (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-269-respectful-maternity-care-disposition-comments.pdf
    January 02, 2024 - This ideology of stratified reproduction persists today in social welfare programs, drug policy and

  20. Prognostic Tests (ppt file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/medical-test-reviews-prognostic.ppt
    June 01, 2012 - Food and Drug Administration and other regulatory agencies have records that can be useful if the test
SHARE:
Facebook Twitter Print Facebook Share

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site:

View results from all sites